Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LSL Pharma GroupTSXV:LSL -1.39%48 EV-to-EBITDA is 246.26 as of Jul. 27, 2026, which is 2506% above its 10-year median of 9.45. GuruFocus rates TSXV:LSL with a GF Score™ of 48/100 and a GF Value™ of C$0.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 742 Drug Manufacturers companies, LSL Pharma Group ranks worse than 98.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LSL Pharma Group's enterprise value is C$87.91 Mil.
LSL Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.36 Mil. Therefore, LSL Pharma Group's EV-to-EBITDA for today is 246.26.
The historical rank and industry rank for LSL Pharma Group's EV-to-EBITDA or its related term are showing as below:
TSXV:LSL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -118.44 Med: 9.45 Max: 608.55
Current: 246.26
During the past 6 years, the highest EV-to-EBITDA of LSL Pharma Group was 608.55. The lowest was -118.44. And the median was 9.45.
TSXV:LSL's EV-to-EBITDA is ranked worse than 98.52% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.93
vs TSXV:LSL: 246.26
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
LSL Pharma Group (TSXV:LSL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LSL Pharma Group's PE Ratio (TTM) for today is calculated as:
LSL Pharma Group's share price for today is C$0.355.
LSL Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for LSL Pharma Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LSL Pharma Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LSL Pharma Group's EV-to-EBITDA falls into.
LSL Pharma Group's current Enterprise Value is C$87.91 Mil.
LSL Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSL Pharma Group (TSXV:LSL) has a EV-to-EBITDA of 246.26 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LSL Pharma Group. This is 2506% above median its historical median of 9.45. According to the industry distribution chart, LSL Pharma Group ranks #731 out of 742 companies in the Drug Manufacturers industry, placing it in the top 98.5%.
Is LSL Pharma Group's EV-to-EBITDA too high?
LSL Pharma Group's current EV-to-EBITDA of 246.26 is 2506% above median its 10-year median of 9.45. The Drug Manufacturers industry median EV-to-EBITDA is 12.93. LSL Pharma Group's value of 246.26 is 1804.6% above this industry median. Based on the distribution chart, LSL Pharma Group ranks #731 out of 742 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, LSL Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #731 out of 742 companies for EV-to-EBITDA. This places LSL Pharma Group in the lower half of its industry. The industry median EV-to-EBITDA is 12.93. LSL Pharma Group's value of 246.26 is 1804.6% above this benchmark. While the company's 10-year median is 9.45 vs. the industry median of 12.93, LSL Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.93, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LSL Pharma Group's current EV-to-EBITDA of 246.26 is 1804.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LSL Pharma Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current EV-to-EBITDA is 246.26, which is 2506% above median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.73, compared to a current price of C$0.36 — trading 51.4% below its estimated fair value. The current EV-to-EBITDA is 246.26, which is 2506% above median its 10-year median of 9.45 and 1804.6% above the Drug Manufacturers industry median of 12.93. LSL Pharma Group's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current EV-to-EBITDA is 246.26 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.36 is trading 51.4% below its estimated GF Value™ of C$0.73.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
EV-to-EBITDA: 246.26 (2506% above median its 10-year median of 9.45)
GF Value™: C$0.73 vs. price of C$0.36 (51.4% below fair value)
Industry Position: 1804.6% above the Drug Manufacturers median (#731 of 742)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
48GF Score
Get the complete analysis for TSXV:LSL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
